𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy

✍ Scribed by Y. Sun; M. Grimmler; V. Schwarzer; F. Schoenen; U. Fischer; B. Wirth


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
201 KB
Volume
25
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis


Communicated by Mark H. Paalman

The autosomal recessive spinal muscular atrophy (SMA), a neuromuscular disease and frequent cause of early death in childhood, is caused in 96% of patients by homozygous absence of the survival motor neuron gene (SMN1). The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. A comprehensive molecular genetic analysis of 34 SMA patients who carry one SMN1 gene is presented, including 18 that were previously published. Haplotype analysis with the microsatellite markers Ag1-CA and C212 in these SMA families turned out to be a reliable accessory method in predicting known SMN1 mutations in SMA patients carrying one SMN1 copy. Five novel missense mutations were identified that are localized in: exon 2a c.88G4A (p.D30N) and c.131A4T (p.D44V); exon 3 c.283G4C (p.G95R) and c.332C4G (p.A111G); and exon 6 c.784A4G (p.S262G), respectively. The survival motor neuron (SMN) protein has been shown to be a component of a large complex (termed the SMN complex) that promotes the formation of spliceosomal U small nuclear ribonucleoproteins (snRNPs). Within this complex, SMN forms oligomers and directly interacts via its N-terminus with SMN-interacting protein 1 (SIP1) and via its central Tudor domain with spliceosomal (Sm) proteins. We performed in vitro interaction studies to test whether SMAcausing missense mutations identified in this study interfere with the reported interactions of SMN. Our results show that mutations p.G95R and p.A111G reduce SMN binding to Sm proteins, further confirming the previous finding that the Tudor domain is the essential binding site of SMN to Sm-proteins. However, all mutations, including those in exon 2a, a region shown to be important for the binding of SMN to SIP1, do not disturb the interaction of SMN to SIP1. Hum Mutat 25:64-71, 2005.


πŸ“œ SIMILAR VOLUMES


In vivo activation of SMN in spinal musc
✍ Lars Brichta; Irmgard Holker; Karsten Haug; Thomas Klockgether; Brunhilde Wirth πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 279 KB πŸ‘ 2 views

## Abstract ## Objective Spinal muscular atrophy results from loss of the survival motor neuron 1 (__SMN1__) gene and malfunction of the remaining __SMN2__. We investigated whether valproic acid can elevate human __SMN__ expression in vivo. ## Methods Blood was collected from 10 spinal muscular

A genetic and phenotypic analysis in Spa
✍ Ivon CuscΓ³; Eva LΓ³pez; Carolina Soler-Botija; MarΓ­a JesΓΊs BarcelΓ³; Montserrat Ba πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 232 KB

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the SMN1 (survival motor neuron) gene. It is classified by age of onset and maximal motor milestones achieved in type I, II, and III (severe, intermediate, and mild form, respectively). Of 369 unrel

Identification and functional analysis o
✍ Silke Sperling; Christina H. Grimm; Ilona Dunkel; Siegrun Mebus; Hans-Peter Sper πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 243 KB

Recent reports have demonstrated that mice lacking the transcription factor Cited2 die in utero showing various cardiac malformations. We present for the first time functionally relevant mutations of CITED2 in patients with congenital heart defects (CHDs). CITED2 encodes a CREBBP/EP300 interacting t